leucine rich repeat and sterile alpha motif containing 1Genealiases: CMT2P · RIFLE · TAL
Q-omics provides the consensus-scored LRSAM1 profile across patient tissues and cancer cell-line models. LRSAM1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LRSAM1 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, LRSAM1 protein abundance shows 20,328 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, COAD, and GBM as cancer lineages where LRSAM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRSAM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRSAM1 survival associations across molecular data types. LRSAM1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRSAM1 RNA expression–survival associations across cancer types. High LRSAM1 expression shows unfavorable associations in ACC, UVM, KIRC and OV, but favorable associations in KIRP and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LRSAM1 RNA expression.
This table summarizes LRSAM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for LRSAM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRSAM1 shows lower tumor expression in BLCA and THCA and higher tumor expression in COAD, HNSC, LIHC and KIRP. The COAD box plot shows higher LRSAM1 RNA expression in tumor versus normal tissue (log2 FC = +0.796, t-test p < 0.001).
This table shows molecular features associated with LRSAM1 in patient tissues and cancer cell lines. In patient samples, LRSAM1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRSAM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BREAST.
